NCT05658562 2026-02-13A Study of MT-2111 in Patients With Relapsed/Refractory DLBCLTanabe Pharma CorporationPhase 1/2 Active not recruiting46 enrolled
NCT05053659 2026-02-12Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin LymphomaCase Comprehensive Cancer CenterPhase 1 Active not recruiting23 enrolled
NCT05971251 2025-10-01Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaUniversity of Alabama at BirminghamPhase 1 Active not recruiting24 enrolled